Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Hydroxychloroquine was granted FDA approval on 18 April 1955.
A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
- Conditions
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 13
- Registration Number
- NCT04334967
- Locations
- 🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States
A Study of Quintuple Therapy to Treat COVID-19 Infection
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- ProgenaBiome
- Target Recruit Count
- 118
- Registration Number
- NCT04334512
- Locations
- 🇺🇸
ProgenaBiome, Ventura, California, United States
A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- ProgenaBiome
- Target Recruit Count
- 600
- Registration Number
- NCT04335084
- Locations
- 🇺🇸
ProgenaBiome, Ventura, California, United States
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Adrian Hernandez
- Target Recruit Count
- 1360
- Registration Number
- NCT04334148
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Marshfield Clinic Health System, Marshfield, Wisconsin, United States
Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection
- Conditions
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 11
- Registration Number
- NCT04335552
- Locations
- 🇺🇸
Durham VA Medical Center, Durham, North Carolina, United States
🇺🇸Duke University Hospital, Durham, North Carolina, United States
🇺🇸Duke Regional Hospital, Durham, North Carolina, United States
Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel
- Conditions
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Plan Nacional sobre el Sida (PNS)
- Target Recruit Count
- 1002
- Registration Number
- NCT04334928
- Locations
- 🇪🇸
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital Rey Juan Carlos, Móstoles, Madrid, Spain
🇪🇸Hospital de Torrejón, Torrejón De Ardoz, Madrid, Spain
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
- Conditions
- Interventions
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 479
- Registration Number
- NCT04332991
- Locations
- 🇺🇸
Harborview Medical Center, Seattle, Washington, United States
🇺🇸University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Maine Medical Center, Portland, Maine, United States
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 221
- Registration Number
- NCT04333225
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2021-05-06
- Target Recruit Count
- 276
- Registration Number
- NCT04332094
- Locations
- 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸Hospital General Universitario de Alicante, Alicante, Valencia, Spain
🇪🇸Hospital General Universitario de Elche, Elche, Valencia, Spain
Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Barcelona Institute for Global Health
- Target Recruit Count
- 275
- Registration Number
- NCT04331834
- Locations
- 🇪🇸
ISGlobal, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.